Logo

PharmaShots Weekly Snapshots (January 17 - 21, 2022)

Share this
PharmaShots Weekly Snapshots (January 17 - 21, 2022)

PharmaShots Weekly Snapshots (January 17 - 21, 2022)

BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

Published: Jan 21, 2022 | Tags: BMS, Abecma, idecabtagene vicleucel, MHLW, Approval, Multiple Myeloma

ASLAN Reports First Patient Enrollment in P-IIb (TREK-AD) Study of ASLAN004 (eblasakimab) for the Treatment of Atopic Dermatitis

Published: Jan 21, 2022 | Tags: ASLAN, P-IIb, TREK-AD Study, ASLAN004, eblasakimab, Atopic Dermatitis

Provention Bio Initiates P-IIa (PREVAIL-2) Study of PRV-3279 for the Treatment of Systemic Lupus Erythematosus

Published: Jan 21, 2022 | Tags: Provention Bio, P-IIa, PREVAIL-2 Study, PRV-3279, Systemic Lupus Erythematosus

Turning Point Reports the US FDA’s IND Clearance of Elzovantinib + Aumolertinib for EGFR Mutant Met-Amplified NSCLC

Published: Jan 21, 2022 | Tags: Turning Point, US, FDA, IND, Elzovantinib, Aumolertinib, EGFR Mutant, Met-Amplified, NSCLC

Merck and Eisai Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III (KEYNOTE-775/Study 309) Trial for Advanced EC

Published: Jan 21, 2022 | Tags: Merck, Eisai, Keytruda, pembrolizumab, Lenvima, Lenvatinib, P-III, KEYNOTE-775, Study 309 Trial, Advanced EC

Eleusis Going Public via Silver Spike SPAC Merger for ~$446M

Published: Jan 21, 2022 | Tags: Eleusis, Going Public, Silver Spike, SPAC, Merger, ~$446M

Sema4 Signs a Definitive Agreement to Acquire GeneDx for ~$623M

Published: Jan 20, 2022 | Tags: Sema4, Acquire, GeneDx, ~$623M

Amgen’s Lumakras (sotorasib) Receives MHLW Approval for the Treatment of Advanced Non-Small Cell Lung Cancer

Published: Jan 20, 2022 | Tags: Amgen, Lumakras, sotorasib, MHLW, Approval, Non-Small Cell Lung Cancer

Vera Seeks to Initiate P-III Clinical Trial of Atacicept for the Treatment of Lupus Nephritis

Published: Jan 20, 2022 | Tags: Vera, P-III, Clinical Trial, Atacicept, Lupus Nephritis

ChemoCentryx’s Tavneos (avacopan) Receives EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis

Published: Jan 20, 2022 | Tags: ChemoCentryx, Tavneos, avacopan, EU, Approval, Tavneos, avacopan, ANCA-Associated Vasculitis

Regeneron Reports the US FDA Acceptance of sBLA for Review of Libtayo (cemiplimab) to Treat Advanced Non-Small Cell Lung Cancer

Published: Jan 20, 2022 | Tags: Regeneron, US, FDA, sBLA, Review, Libtayo, cemiplimab, Non-Small Cell Lung Cancer

AstraZeneca Reports Results of Imfinzi + tremelimumab in P-III (HIMALAYA) Trial for the Treatment of Hepatocellular Carcinoma

Published: Jan 20, 2022 | Tags: AstraZeneca, Imfinzi, tremelimumab, P-III, HIMALAYA Trial, Hepatocellular Carcinoma

UCB Signs a Definitive Agreement to Acquire Zogenix for ~$1.9B

Published: Jan 19, 2022 | Tags: UCB, Acquire, Zogenix, ~$1.9B

Sanofi Reports Results of Dupixent (dupilumab) in P-III (PRIME) Trial for the Treatment of Prurigo Nodularis

Published: Jan 19, 2022 | Tags: Sanofi, Dupixent, dupilumab, P-III, PRIME Trial, Prurigo Nodularis

Exelixis Presents Results for Cabozantinib in P-Ib (COSMIC-021) & P-II (CAMILLA) Trial for Advanced Colorectal Cancer at ASCO GI 2022

Published: Jan 19, 2022 | Tags: Exelixis, Cabozantinib, P-Ib, COSMIC-021, P-II, CAMILLA Trial, Advanced Colorectal Cancer,  ASCO GI 2022

23andMe Extends its 2018 Collaboration with GSK for CD96 Program to Treat Cancer

Published: Jan 19, 2022 | Tags: 23andMe, 2018, GSK, CD96 Program, Cancer

AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III (TOPAZ-1) Trial as 1L Treatment of Advanced Biliary Tract Cancer

Published: Jan 19, 2022 | Tags: AstraZeneca, Imfinzi, durvalumab, P-III, TOPAZ-1 Trial, Advanced Biliary Tract Cancer

Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-394) Trial for the Treatment of Advanced HCC at ASCO GI 2022

Published: Jan 19, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-394 Trial, Advanced, HCC, ASCO GI 2022

ADC Entered an Exclusive License Agreement with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Japan

Published: Jan 18, 2022 | Tags: ADC, Mitsubishi Tanabe Pharma Corporation, Zynlonta, loncastuximab tesirine-lpyl, Japan

Lilly Entered into a Collaboration with Evotec to Develop Therapies for Diabetes and Chronic Kidney Diseases

Published: Jan 18, 2022 | Tags: Lilly, Evotec, Diabetes, Chronic Kidney Diseases

Pfizer’s Paxlovid (nirmatrelvir and ritonavir) Receives Health Canada’s Approval for the Treatment of COVID-19

Published: Jan 18, 2022 | Tags: Pfizer, Paxlovid, nirmatrelvir, ritonavir, Health Canada, Approval, COVID-19

Lilly Entered into an Exclusive License Agreement with Abbisko to Develop Novel Therapies for Cardiometabolic Diseases

Published: Jan 18, 2022 | Tags: Lilly, Abbisko, Novel Therapies, Cardiometabolic Diseases

Neurimmune Expands its Collaboration with Ono to Develop Monoclonal Antibody Therapies for the Treatment of Neurodegenerative Diseases

Published: Jan 18, 2022 | Tags: Neurimmune, Ono, Antibody Therapies, Neurodegenerative Diseases, RTM Technology Platform

CANbridge Reports NMPA Acceptance of NDA for AN108 to Treat Alagille  Syndrome

Published: Jan 18, 2022 | Tags: CANbridge, NMPA, NDA, AN108, Alagille Syndrome

Ascletis’s ASC22 (envafolimab) Receives US FDA’s IND Approval of ASC22 (envafolimab) for the Treatment of Chronic Hepatitis B

Published: Jan 17, 2022 | Tags: Ascletis, ASC22, envafolimab, US, FDA, IND, Approval, ASC22, envafolimab, Chronic Hepatitis B

Medtronic Reports Three Months Results of DTM Spinal Cord Stimulation Endurance Therapy for the Treatment of Chronic Pain

Published: Jan 17, 2022 | Tags: Medtronic, DTM Spinal Cord Stimulation Endurance Therapy, Chronic Pain

Pfizer’s Cibinqo (abrocitinib) Receives the US FDA’s Approval for the Treatment of Atopic Dermatitis

Published: Jan 17, 2022 | Tags: Pfizer, Cibinqo, abrocitinib, US, FDA, Approval, Atopic Dermatitis

AstraZeneca Reports Results of Vaxzevria as Third Dose Booster in Multiple Trial for the Treatment of COVID-19

Published: Jan 17, 2022 | Tags: AstraZeneca, Vaxzevria, D7220C00001 Trial, COVID-19

Dermavant Reports Results of Tapinarof in P-III (PSOARING 3) Study for the Treatment of Plaque Psoriasis

Published: Jan 17, 2022 | Tags: Dermavant, Tapinarof, P-III, PSOARING 3 Study, Plaque Psoriasis

AbbVie’s Rinvoq (upadacitinib) Receives the US FDA’s Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Published: Jan 17, 2022 | Tags: AbbVie, Rinvoq, upadacitinib, US, FDA, Approval, Atopic Dermatitis

Related Post: PharmaShots Weekly Snapshots (January 10 - 14, 2022)


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions